Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A PhaseⅠFood-Effect Study of Hemay022 in Healthy Subjects
The primary objective of this study is to determine the effect of food in healthy participants on the bioavailability of Hemay022 following single dose administration with and without a meal.
A Dose Escalation Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Hemay102 in Patients With Advanced Solid Tumors
This trial was a single-center, open-label, dose-increasing Phase I clinical study with subjects enrolled in patients with advanced solid tumors who failed standard treatment or who were unable to receive effective treatment. The trial is divided into two stages: dose escalation and dose extension.
100 Clinical Results associated with Tianjin Hemei Aokang Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Tianjin Hemei Aokang Pharmaceutical Technology Co., Ltd.
100 Deals associated with Tianjin Hemei Aokang Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Tianjin Hemei Aokang Pharmaceutical Technology Co., Ltd.